Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm multicenter study of human coagulation factor IX in moderate to severe hemophilia B
CTR20250826Phase 3Completed
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human coagulation factor IX in hemophilia B (HB), sponsored by Chengdu Rongsheng Pharmaceutical. Started Mar 2025; status: completed.
02
Drugs
human coagulation factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20250826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250826.